ClinicalTrials.gov
public full text
Public Domain
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients#836539
- Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis#1263047
- Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis#1100361
- Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)#894523
- Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses#883943
Record · ID 1213454
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive